Anti-Estorgen Steroids Powder Raloxifene Hydrochloride CAS No: 82640-04-8

Quick Detail:

Name:Raloxifene Hydrochloride

CAS No: 82640-04-8

Purity: 99%

Molecular formula: C28H28ClNO4S

Molecular Weight: 510.04

Appearance: Light yellow solid

Nominal Mass: 509 Da

Average Mass: 510.0442 Da

Monoisotopic Mass: 509.142756 Da

Flash Point: 394.2 °C

Enthalpy of Vaporization: 110.08 kJ/mol

Boiling Point: 728.2 °C at 760 mmHg

Vapour Pressure: 6.46E-22 mmHg at 25 °C

Solubility: DMSO: 28 mg/mL, soluble

Specification: USP30/BP2005

Packing: as your requires

Standard:Enterprise Standard 

Price:negotiable 

MOQ:10g

Trade Mark:CQSP

Production Capacity:5000kg/month

Shipping: DHL, EMS, FedEx, UPS

Shelf life:2 years

More details pls contact:Whatapp:86 13048470428  

Skype/E-mail : summer at chembj.com

Description of Raloxifene hydrochloride

Raloxifene hydrochloride is a second-generation Selective Estrogen Receptor Modulator (SERM) of the benzothiophene family.This drug is similar in effect to tamoxifen, exhibiting estrogen receptor antagonist (blocking) properties in some tissues while acting as an estrogen receptor agonist (activator) in others.

The main point of variation between these two agents is their tissue selectivity.While raloxifene hydrochloride is a strong anti-estrogen in breast and uterine tissues,it appears to be estrogenic in bone.This allows it to protect bone density,mimicking the beneficial effects of endogenous estradiol.This is quite different from tamoxifen,which is anti-estrogenic in both breast and bone.

In a role that was novel for an anti-estrogen,raloxifene hydrochloride was approved by the FDA for the prevention and treatment of osteoporosis in post-menopausal women.It is also being investigated for several other potential uses,including the treatment and prevention of cardiovascular disease,breast cancer,gynecomastia, prostate cancer,acromegaly,and uterine cancer.

Raloxifene hydrochloride Mechanism of Action:

Evista (raloxifene hydrochloride) is an estrogen agonist/antagonist,referred to as a selective estrogen receptor modulator (SERM) and belongs to the benzothiophene class of compounds.The biological actions of raloxifene are largely mediated through binding to estrogen receptors.

This binding results in activation of estrogenic pathways in some tissues (agonism) and and the blockade of estrogenic pathways in other tissues (antagonism).The agonistic or antagonistic activity of raloxiffene depends on the extent of recruitment of coactivators and corepressors to estrogen receptor (ER) target gene promotors.

Raloxifene appears to act as an estrogen agonist in bone.It decreases bone resorption and bone turnover, increases bone mineral density and decreases fracture incidence.

Applications:

Reduction in the incidence of invasive breast cancer in postmenopausal women with osteoporosis. in 2006, the National Cancer Institute announced that raloxifene was as effective as tamoxifen in reducing the incidence of breast cancer in postmenopausal women at increased risk, EVISTA (raloxifene hydrochloride) is an estrogen agonist / antagonist, commonly referred to as a selective estrogen receptor modulator (SERM) that belongs to the benzothiophene class of compounds.